Clinical Trials Logo

Filter by:
NCT ID: NCT06445114 Not yet recruiting - Carcinoma Clinical Trials

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

Start date: July 2024
Phase: Phase 2
Study type: Interventional

This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph nodes.

NCT ID: NCT06445075 Recruiting - Clinical trials for Overweight and Obesity

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

EMBRAZE
Start date: May 21, 2024
Phase: Phase 2
Study type: Interventional

A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 agonist therapy in subjects with overweight or obesity

NCT ID: NCT06445062 Recruiting - Colorectal Cancer Clinical Trials

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Start date: May 24, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The first three subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel

NCT ID: NCT06445010 Recruiting - Music Therapy Clinical Trials

Musical Playlist of the Grief Journey

Start date: June 11, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about the effectiveness of a music-based intervention as a bereavement strategy for individuals who are a part of the Loss of Spouse/Life Partner Grief Support Group at HopeHealth, a healthcare organization in Providence, Rhode Island that specializes in home care, hospice care, palliative care, and grief support. The main question it ams to answer is: - Will the experience of creating a musical playlist help individuals in bereavement process their grief more effectively? Participants will undergo the following main tasks: - A baseline pre-assessment survey that asks about the role of music in the participant's and their partner's life, as well as how music has helped participants with their grief. - A 75-minute Zoom session with the study investigator which includes a conversation about the participant's loved one and grief journey. This Zoom session serves to find themes and emotions in the participant's grief journey which will be as foundations for musical playlists. - Participants will create their own musical playlist based on guidance from the study investigator. - A post-assessment survey that asks participants to reflect on the experience of creating a playlist. This survey also examines if music plays a new role in the participant's life.

NCT ID: NCT06444984 Recruiting - Hyperinsulinemia Clinical Trials

The Movie Theater Study

Start date: March 24, 2024
Phase: N/A
Study type: Interventional

Increasing attention has been paid to meals with unusual characteristics that are consumed on a semi-regular basis (e.g., "tailgating," pizza buffets). The purpose of this study is to describe the acute cardiometabolic effects of a cinema-style meal rich in refined sugar, total carbohydrate, and moderate in fat (i.e., soda, popcorn, candy).

NCT ID: NCT06444880 Not yet recruiting - Clinical trials for SMARCB1-Deficient Malignancies

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Start date: November 29, 2024
Phase: Phase 2
Study type: Interventional

To find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).

NCT ID: NCT06444841 Not yet recruiting - Alzheimer Disease Clinical Trials

Paper-Based and Smartphone-Based Memory Supports

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Alzheimer's disease and related dementias lead to marked declines in daily functioning, independence, and quality of life. One of the earliest cognitive changes in these conditions is impairment in prospective memory, or the ability to remember future intentions such as taking medications at a given time. Prior intervention studies that targeted prospective memory used mnemonic strategies or cognitive training, but these approaches resulted in modest gains in clinical populations. By contrast, a Stage I pilot trial indicated that smartphone-based memory aids (reminder apps) can be accepted and used by persons with mild cognitive impairment and mild dementia to improve both subjective and objective prospective memory performance. The investigators will now test for efficacy, durability, and generalizability of benefits across diverse samples in a Stage II randomized controlled trial. Some 200 participants with mild cognitive impairment or mild dementia will be recruited, half of whom will be from digitally-disadvantaged backgrounds (low socioeconomic status, rural, or historically underrepresented groups). Participants will complete baseline assessments and then be randomly assigned to a smartphone reminder app intervention or an active control condition that uses a paper- based memory support system. Across a 4-week intervention period, participants will complete patient-selected and experimenter-assigned prospective memory assessments and receive booster training sessions to promote self-efficacy with the intervention/control system. Durability of effects will be assessed at 3-month and 6-month follow-up sessions. As a secondary aim, study partners will be simultaneously enrolled to collect informant ratings, track how much study partners assist the participants, and determine whether improving prospective memory in patients improves quality of life in study partners (e.g., by reducing the double to-do list burden of remembering for themselves and for care recipients). As a third aim, the investigators will identify barriers and facilitators to smartphone interventions in digitally-disadvantaged individuals who have historically been underrepresented in technology and dementia research.

NCT ID: NCT06444594 Not yet recruiting - Aging Clinical Trials

Transient Receptor Potential Channels

TRP
Start date: June 15, 2024
Phase: Early Phase 1
Study type: Interventional

Neurovascular signaling in the skin associated with stimulation of the transient receptor potential (TRP) channels. These channels are stimulated by both temperature and naturally occurring bioactive agents found in mint, chili peppers, garlic, etc. The aim of the study is to examine how topically applied TRP channel agonists including menthol, capsaicin and camphor impact neurovascular responses in the skin.

NCT ID: NCT06444542 Not yet recruiting - Colo-rectal Cancer Clinical Trials

Understanding Patient Preference on Colorectal Cancer Screening Options-PSU

U-Screen
Start date: May 25, 2024
Phase:
Study type: Observational

There are significant barriers to colorectal cancer screening within underserved populations due to the cost, accessibility, and acceptability of screening methods. Patient-friendly approaches that minimize stress and discomfort for the patient are needed to enhance screening compliance and achieve an early diagnosis. The primary aim of this study is to examine whether the availability of a blood-based screening option, which can be done at the point of service and is familiar to patients, will improve patient compliance to recommended CRC screening

NCT ID: NCT06444529 Not yet recruiting - Ocular Redness Clinical Trials

A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness

Start date: August 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of Apraclonidine Hydrochloride Ophthalmic Solution 0.125% when compared to Vehicle, in relieving redness of the eye due to minor eye irritations. This study will be conducted in the United States.